FSD Pharma [HUGE] vs Haleon Plc - ADR [HLN] Detailed Stock Comparison

FSD Pharma Inc.

NASDAQ
Loading...

Haleon Plc - ADR

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: FSD Pharma Inc. wins in 2 metrics, Haleon Plc - ADR wins in 12 metrics, with 0 ties. Haleon Plc - ADR appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric FSD Pharma Inc. Haleon Plc - ADR Better
P/E Ratio (TTM) -0.18 18.72 Haleon Plc - ADR
Price-to-Book Ratio 0.01 1.88 FSD Pharma Inc.
Debt-to-Equity Ratio 6.13 52.37 FSD Pharma Inc.
PEG Ratio -0.75 15.42 Haleon Plc - ADR
EV/EBITDA -0.03 33.08 Haleon Plc - ADR
Profit Margin (TTM) 0.00% 15.11% Haleon Plc - ADR
Operating Margin (TTM) 0.00% 23.17% Haleon Plc - ADR
EBITDA Margin (TTM) N/A 23.17% N/A
Return on Equity -63.89% 10.27% Haleon Plc - ADR
Return on Assets (TTM) -36.47% 4.67% Haleon Plc - ADR
Free Cash Flow (TTM) $-10.83M $2.22B Haleon Plc - ADR
Dividend Yield N/A 1.63% N/A
1-Year Return -92.53% -16.01% Haleon Plc - ADR
Price-to-Sales Ratio (TTM) N/A 3.78 N/A
Enterprise Value $287,159 $122.54B Haleon Plc - ADR
EV/Revenue Ratio N/A 8.23 N/A
Gross Profit Margin (TTM) N/A 55.38% N/A
Revenue per Share (TTM) $0 $2 Haleon Plc - ADR
Earnings per Share (Diluted) $-16.25 $0.50 Haleon Plc - ADR
Beta (Stock Volatility) N/A 0.33 N/A
Short % of Float N/A 0.43% N/A

FSD Pharma Inc. vs Haleon Plc - ADR Stock Performance Analysis

Loading Price Chart...

HUGE
HLN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
FSD Pharma Inc.12.29%N/AN/AN/AN/AN/A
Haleon Plc - ADR-0.66%2.02%1.23%-13.29%-7.73%-9.30%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
FSD Pharma Inc.-92.53%-94.20%-98.33%-99.52%-99.52%-99.52%
Haleon Plc - ADR-16.01%8.43%23.21%23.21%23.21%23.21%

Performance & Financial Health Analysis: FSD Pharma Inc. vs Haleon Plc - ADR

MetricHUGEHLN
Market Information
Market Cap iN/A$42.40B
Market Cap CategoryN/ALarge cap
10 Day Avg. Volume i82,6636,594,249
90 Day Avg. Volume i62,7797,985,230
Last Close$5.39$9.07
52 Week Range$3.50 - $97.50$8.65 - $11.28
% from 52W High-94.47%-19.59%
All-Time High$11,432.16 (Sep 10, 2018)$11.42 (Jun 02, 2025)
% from All-Time High-99.95%-20.58%
Growth Metrics
Quarterly Revenue GrowthN/A0.01%
Quarterly Earnings GrowthN/A0.86%
Financial Health
Profit Margin (TTM) i0.00%0.15%
Operating Margin (TTM) i0.00%0.23%
Return on Equity (TTM) i-0.64%0.10%
Debt to Equity (MRQ) i6.1352.37
Cash & Liquidity
Book Value per Share (MRQ)$17.09$4.99
Cash per Share (MRQ)$5.19$0.15
Operating Cash Flow (TTM) i$-5,144,110$3.56B
Levered Free Cash Flow (TTM) i$-10,054,595$1.89B
Dividends
Last 12-Month Dividend Yield iN/A1.63%
Last 12-Month Dividend iN/A$0.17

Valuation & Enterprise Metrics Analysis: FSD Pharma Inc. vs Haleon Plc - ADR

MetricHUGE (Mar 31, 2025)HLN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-0.1818.72
Forward P/E i-0.7515.42
PEG Ratio i-0.7515.42
Price to Sales (TTM) iN/A3.78
Price to Book (MRQ) i0.011.88
Market Capitalization
Market Capitalization i$66,671$42.40B
Enterprise Value i$287,159$122.54B
Enterprise Value Metrics
Enterprise to Revenue iN/A8.23
Enterprise to EBITDA i-0.0333.08
Risk & Other Metrics
Beta iN/A0.33
Book Value per Share (MRQ) i$17.09$4.99

Financial Statements Comparison: FSD Pharma Inc. vs Haleon Plc - ADR

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricHUGE (2023)HLN (2025)
Revenue/Sales i011.03B
Cost of Goods Sold iN/A3.95B
COGS % of Revenue i-35.8%
Gross Profit iN/A7.08B
Gross Margin i-64.2%
Research & Development i3.86M316.00M
Operating Income (EBIT) i-19.57M2.41B
Operating Margin i-21.9%
EBITDA i-11.34M2.81B
EBITDA Margin i-25.5%
Pre-Tax Income i-18.23M2.15B
Pre-Tax Income % of Revenue i-19.5%
Income Tax iN/A472.00M
Income Tax % of Revenue i-4.3%
Net Income (Profit) i-18.23M1.68B
Profit Margin i-15.2%

Balance Sheet & Liquidity Metrics

MetricHUGE (2023)HLN (2025)
Cash & Equivalents i2.76M1.26B
Total Current Assets i11.09M4.55B
Total Current Assets % of Revenue i-41.3%
Total Current Liabilities i4.57M4.93B
Total Current Liabilities % of Revenue i-44.7%
Long-Term Debt i07.75B
Long-Term Debt % of Revenue i-70.2%
Total Shareholders Equity i12.91M16.48B
Retained Earnings i-157.91M27.85B
Retained Earnings % of Revenue i-252.5%
Property, Plant & Equipment i120,4211.00M

Cash Flow Statement Comparison

MetricHUGE (2023)HLN (2025)
Operating Cash Flow i-17.53M2.19B
Operating Cash Flow % of Revenue i-19.8%
Capital Expenditures i0-322.00M
Free Cash Flow i-10.83M2.22B
FCF Margin i-20.1%
Debt Repayment i-189,054-1.35B
Common Stock Repurchase i-2.96M-654.00M

Short Interest & Institutional Ownership Analysis

MetricHUGEHLN
Shares Short iN/A19.28M
Short Ratio iN/A2.14
Short % of Float iN/A0.43%
Shares Outstanding i605,7968.91B
Float Shares i600,6968.86B
% Held by Insiders i9.74%0.01%
% Held by Institutions i2.69%12.74%
% Held by Public i87.57%87.25%

Dividend Analysis & Yield Comparison: FSD Pharma Inc. vs Haleon Plc - ADR

MetricHUGEHLN
Last 12-Month Dividend iN/A$0.17
Last 12-Month Dividend Yield iN/A1.63%
3-Year Avg Annual Dividend iN/A$0.11
3-Year Avg Dividend Yield iN/A0.91%
3-Year Total Dividends iN/A$0.34
Ex-Dividend DateN/AApr 25, 2025